Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cART for PBC Unresponsive to UDCA
NCT03954327Phase 2Completed
- Sponsor
- University of Alberta
- Start
- Mar 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of emtricitabine, tenofovir disoproxil fumarate and raltegravir in primary biliary cholangitis (PBC) (2 arms), sponsored by University of Alberta. Primary endpoint: Change in mean percentage of alkaline phosphatase reduction at 12 months. Started Mar 2021; status: completed.
02
Drugs
emtricitabinetenofovir disoproxil fumarateraltegravir
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03954327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954327.